KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Total Current Liabilities (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Total Current Liabilities for 17 consecutive years, with $759.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 25.05% year-over-year to $759.0 million, compared with a TTM value of $759.0 million through Dec 2025, up 25.05%, and an annual FY2025 reading of $759.0 million, up 25.05% over the prior year.
  • Total Current Liabilities was $759.0 million for Q4 2025 at Biomarin Pharmaceutical, down from $798.4 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $1.2 billion in Q4 2023 and bottomed at $443.3 million in Q2 2021.
  • Average Total Current Liabilities over 5 years is $740.6 million, with a median of $656.2 million recorded in 2025.
  • The sharpest move saw Total Current Liabilities surged 123.26% in 2023, then tumbled 48.43% in 2024.
  • Year by year, Total Current Liabilities stood at $546.5 million in 2021, then rose by 7.76% to $588.9 million in 2022, then skyrocketed by 99.87% to $1.2 billion in 2023, then plummeted by 48.43% to $607.0 million in 2024, then rose by 25.05% to $759.0 million in 2025.
  • Business Quant data shows Total Current Liabilities for BMRN at $759.0 million in Q4 2025, $798.4 million in Q3 2025, and $684.2 million in Q2 2025.